FDA Approves First Treatment for Advanced Dry AMD
Patients and doctors across the country are celebrating a monumental moment in the history of retinal care: the first treatment for advanced dry AMD (geographic atrophy) has been FDA-approved. Through monthly and bi-monthly pegcetacoplan injections, the studies demonstrated a meaningful reduction of lesion growth in patients with advanced dry AMD.